ICAM1 and rheumatoid arthritis: In a model of RA driven by autoantibodies, treatment with anti–JAM-A mAb delayed the disease onset and partially ameliorated overall disease, similar to the effect observed after treatment with anti-ICAM1, another LFA-1 ligand (29).